Why the study?
Does clopidogrel improve systemic endothelial nitric oxide bioavailability and reduce biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease?
Does clopidogrel improve systemic endothelial nitric oxide bioavailability and reduce biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease?
Clopidogrel demonstrates pleiotropic vasoprotective effects in CAD patients by improving endothelial nitric oxide bioavailability and reducing oxidative stress and inflammation, extending its benefits beyond simple platelet inhibition.
May support pleiotropic endothelial benefits in CAD; leaves open clinical outcome impact.
Clopidogrel improves endothelial nitric oxide bioavailability and diminishes biomarkers of oxidant stress and inflammation in patients with symptomatic coronary artery disease, suggesting that beyond inhibition of platelet aggregation, adenosine phosphate receptor blockade may also have promising vasoprotective effects.
No takes yet. Share an insight, caveat, or question.
Heitzer et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: